Heparin-induced thrombocytopenia: An update for the COVID-19 era.
S Afr Med J
; 111(9): 841-848, 2021 07 20.
Article
in English
| MEDLINE | ID: covidwho-1404039
ABSTRACT
The increased use of heparin during the current COVID-19 pandemic has highlighted the risk of a rare but potentially serious complication of heparin therapy, viz. heparin-induced thrombocytopenia (HIT). This is a short review on the pharmacology of heparin and its derivatives, and the pathophysiology of HIT. Guidance on laboratory testing for and clinical management of HIT is presented in accordance with international guidelines. There are important similarities and differences between HIT and the new entity of vaccine-induced immune thrombotic thrombocytopenia, also known as thrombosis with thrombocytopenia syndrome, which clinicians need to be aware of.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombocytopenia
/
Heparin
/
COVID-19
/
Anticoagulants
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
S Afr Med J
Year:
2021
Document Type:
Article
Affiliation country:
SAMJ.2021.v111i9.15909
Similar
MEDLINE
...
LILACS
LIS